Vistagen Therapeutics, Inc.
refisolone
vasomotor symptoms (hot flashes) due to menopause
Resolved
7days ago
Catalyst readout · ~ Jun 30, 2026 estimated
What's at stake
A key catalyst for refisolone (vasomotor symptoms (hot flashes) due to menopause) is expected ~ Jun 30, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Vistagen is currently preparing an Investigational New Drug application (IND) for submission to the U.S. Food and Drug Administration (FDA), with a planned submission in the first half of 2026.”